Phase 2 N=24 Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy
Alveolar Bone Loss
Primary: Bone Regeneration — 79; 63 % bone height
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=480 Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease
Primary: Change From Baseline in Percent Regurgitation-Free Days Over Weeks 5-8 — 36.96; 43.01; 44.37; 38.79 percentage of days — p=0.128
Phase 2 N=242 A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
Melanoma
Primary: Number of Participants With On-study Adverse Events (AEs), AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related AEs, Immune-related AEs (irAEs)…
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
Phase 2 N=397 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
Female Sexual Arousal Disorder · Hypoactive Sexual Desire Disorder
Primary: The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE) — 0.2; 0.6; 0.7; 0.8 SSEs — p=<0.05
Phase 2 N=24 Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
Cervical Ripening · Induction of Labor
Primary: Time of Maximum Plasma Concentration (Tmax) of Misoprostol After Insertion — 4 hours
Phase 2 N=8 Phase 2a, Exploratory Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of XPF-002 in Patients With Primary/Inherited Erythromelalgia
Primary Erythromelalgia · Inherited Erythromelalgia
Primary: Average Daily Use of Cooling for Erythromelalgia-Related Pain in Treatment Period 2 — 0.24; 2.4 cooling uses/day
Phase 2 N=135 Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in 24-hour Mean Ambulatory SBP — 4.3; 1.3 mmHg — p=0.023
Phase 2 N=20 An Outpatient Pump Shutoff Pilot Feasibility and Safety Study
Type 1 Diabetes
Primary: Mean Morning Blood Glucose (mg/dL)- Algorithm 1 — 158; 125 mg/dl
Phase 2 N=61 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
Hematologic Malignancies · Graft vs Host Disease
Primary: 100-day Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GVHD) — 22 percentage of participants
Phase 2 N=37 Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children
HIV Infections
Primary: Maximum Observed Plasma Concentration (Cmax) and Plasma Concentration 24 Hours Post-dose (Cmin) of EFV at Week 2 - Pharmacokinetic Evaluable Population — 3790; 1998…
Phase 2 N=128 Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Primary: Percentage of Relapse Free Subjects (no Relapse) — 56.8; 59.5; 68.3; 43.2 percentage of participants — p=0.221
Phase 2 N=43 Evaluation of SAMe for Hot Flashes
Healthy, no Evidence of Disease · Hot Flashes
Primary: Percent of Baseline in Average Hot Flash Activity (Score and Frequency) — 64.6; 67.4 Percent of baseline — p=0.0903
Phase 2 N=307 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia
Alopecia · Alopecia, Androgenetic · Baldness
Primary: Change From Baseline in Target Area Hair Count (TAHC) — 135.0; 145.7; 151.5; 143.7 terminal hairs/cm^2
Phase 2 N=26 Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Complete Response (CR) — 2; 21 participants